Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 6
BPC-157 dosing: what the studies used
No validated human dose for BPC-157 exists. The 200 to 500 mcg range quoted online is an allometric extrapolation from rodent injury models, not clinical data.
Is BPC-157 legal? Status by country
BPC-157 is not approved for human use in any country we cover. Here is the regulatory status across the US, EU, and UK as of mid-2026.
What is BPC-157? A plain-English explainer
BPC-157 is a synthetic peptide from human gastric juice studied in rodents for tissue repair. No controlled human trial exists, and it is not approved anywhere.
Semaglutide vs tesamorelin compared
Semaglutide and tesamorelin are both FDA-approved peptides, but their regulatory paths, evidence bases and grey-market exposure could not be more different.
ACP review: which obesity drugs pay off?
A new ACP systematic review rates tirzepatide high-value but flags poor study quality across all obesity drug cost models.
ACP: tirzepatide, semaglutide first-line
A living ACP guideline published 16 June 2026 places tirzepatide and semaglutide first among pharmacologic obesity treatments for US outpatient adults.
GLP-1 drugs and plastic surgery risks
A 2026 review examines wound risks, aspiration concerns and body-contouring challenges when aesthetic surgery patients use GLP-1 agonists.
Medicare's $50 GLP-1 bridge may never end
A temporary Medicare program offers GLP-1 weight-loss drugs for $50 a month from July 2026. It has already been extended once.
Low-dose semaglutide cuts weight in HARMONY
The HARMONY cohort from China reports 9.9% mean weight loss at 24 weeks on semaglutide 0.5 or 1.0 mg weekly, below the 2.4 mg obesity dose.
Semaglutide and pancreatic cancer risk
A 2026 meta-analysis of randomised trials found no increased pancreatic cancer risk with semaglutide, consistent with two earlier reviews of the GLP-1 class.
Semaglutide QoL gains: real but modest
A 2026 meta-analysis finds semaglutide 2.4 mg improves physical functioning scores, but gains fall below clinically meaningful thresholds.
Semaglutide vs dulaglutide in UK practice
A UK cohort study of 6,616 adults found semaglutide lowered HbA1c by 0.22 points more than dulaglutide over one year, with 1.92 kg more weight loss.